Abstract
New oral anticoagulants (NOACs), including direct thrombin and factor Xa inhibitors, have several advantages over vitamin K antagonists with regard to the prevention and treatment of thromboembolic events. However, clinical and postmarketing evidence suggests that all of the currently available NOACs carry a small risk of hepatotoxicity. The mechanism behind this idiosyncratic adverse drug reaction remains unclear. Physicians and patients should be aware of the possible risks of liver injury with NOACs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
